Ponatinib

Key driver for ARIAD Pharmaceuticals (NASDAQ: ARIA) is ponatinib in pivotal Ph2, targeting well-defined/proven CML market (data 2H12), Jefferies reports. “As we assume no further milestones from MRK on ridaforolimus, if Ph3 succeeds (data in 1Q11), this would provide a significant upside to current...